732P Durvalumab + carboplatin/paclitaxel (CP) followed by durvalumab ± olaparib as a first-line treatment for endometrial cancer (EC): Progression-free survival (PFS) by clinical factors in DUO-E
Blank, S.V., McCollum, M., Anderson, C., Pennington, K., Salinas, E., Richardson, D.L., Slomovitz, B.M., Kim, B-G., Liu, J., Mori, M., Guette, P.L. Ramos, Joseph de Pádua, C., Martinez-Garcia, J., Papadimitriou, C., Grisan, K., Póka, R.L., Kowgier, M., Del Rosario, P.M.D., Van Nieuwenhuysen, E., Westin, S.
Published in Annals of oncology (01.09.2024)
Published in Annals of oncology (01.09.2024)
Get full text
Journal Article
1370P Detection of mutations in homologous recombination repair (HRR) genes in tumour tissue (TT) and circulating tumour DNA (ctDNA) from patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) in the phase III PROpel trial
Armstrong, A.J., Saad, F., Thiery-Vuillemin, A., Oya, M., Shore, N.D., Mehra, N., Ozguroglu, M., Gedye, C., Sartor, O., Poehlein, C.H., Qiu, P., Liu, Y-Z., Riva, L., Harrington, L., Barker, L., Del Rosario, P.M.D., Barnicle, A., Clarke, N.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
157O Biomarker analysis and updated results from the phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Oya, M., Armstrong, A.J., Thiery-Vuillemin, A., Shore, N., Procopio, G., Arslan, Ç., Mehra, N., Parnis, F., Brown, E., Constans Schlurmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Liu, Y-Z., Poehlein, C.H., Desai, C., Del Rosario, P.M.D., Clarke, N., Saad, F.
Published in Annals of oncology (01.11.2022)
Published in Annals of oncology (01.11.2022)
Get full text
Journal Article
1357O Biomarker analysis and updated results from the Phase III PROpel trial of abiraterone (abi) and olaparib (ola) vs abi and placebo (pbo) as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Saad, F., Armstrong, A.J., Thiery-Vuillemin, A., Oya, M., Shore, N.D., Procopio, G., Arslan, C., Mehra, N., Parnis, F., Brown, E., Constans Schlurmann, F., Joung, J.Y., Sugimoto, M., Sartor, O., Liu, Y-Z., Poehlein, C.H., Desai, C., Del Rosario, P.M.D., Clarke, N.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article